## Lupin Limited (LUPIN) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Lupin Limited is a pharmaceutical company listed on the National Stock Exchange of India (NSE) since September 10, 2001.  It operates in the Pharmaceuticals industry and holds a significant position within the Indian pharmaceutical sector, known for its generic and specialty drug manufacturing and marketing.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                                 |
|-----------------------------|-----------------|-------------------------------------------------------------------------|
| Current Price               | ₹2,149.75       |                                                                         |
| Percentage Change (PChange) | -0.61%          | Negative change indicating a slight downward trend in the current session. |
| Pre-Open Activity          | ₹2,165          | Higher than the previous close, suggesting potential buying interest.     |
| Week High                    | ₹2,312          | High price achieved during the week.                                   |
| Week Low                     | ₹1,200.15       | Low price achieved during the week, indicating significant volatility.   |
| VWAP                        | ₹2,161.83       | Volume Weighted Average Price for the day.                             |
| Sector PE                   | 37.21           | Price-to-Earnings ratio for the sector.                               |
| Symbol PE                   | 37.21           | Price-to-Earnings ratio for Lupin Limited.                             |
| Delivery Percentage         | 49.24%          | Relatively high delivery percentage suggests some degree of conviction. |
| Market Depth                | Low              | Order book data shows low market depth, indicating potential for price swings. |


**3. Financial Performance:**

The following table summarizes Lupin's financial performance over the past five quarters.  Note that the data shows a profit after tax, which contradicts the provided "proLossAftTax" values.  Further investigation into the data source is recommended to clarify this discrepancy.  The analysis below assumes the provided "proLossAftTax" values are correct, representing losses.

| Quarter Ending      | Revenue (₹)     | Expenses (₹)    | Profit After Tax (₹) | EPS (₹) |
|----------------------|-----------------|-----------------|-----------------------|---------|
| 30-Sep-2024          | 413,882         | 315,477         | -80,776               | -17.71  |
| 30-Jun-2024          | 420,585         | 312,293         | -88,918               | -19.51  |
| 31-Mar-2024          | 342,722         | 299,906         | -38,408               | -8.43   |
| 31-Dec-2023          | 413,891         | 305,495         | -91,644               | -20.14  |
| 30-Sep-2023          | 368,483         | 298,879         | -54,861               | -12.06  |


**Key Financial Ratios:**  Further analysis requires additional financial data (e.g., assets, liabilities, etc.) to calculate meaningful ratios like Return on Equity (ROE), Debt-to-Equity ratio, etc.  The provided data is insufficient for a comprehensive ratio analysis.  The current data shows consistent losses over the past five quarters.

**4. Corporate Actions and Announcements:**

* **Dividends:** Lupin has a history of paying dividends, with recent payouts of ₹8 per share (ex-date July 16, 2024), ₹4 per share (July 14, 2023), and others in previous years.
* **Announcements:** Recent announcements include information on capital alteration, ESOPs, rumour verifications, press releases, and loss/duplicate share certificates.  These announcements require further review to assess their impact on the stock price.  The notes to the financial statements reveal significant corporate restructuring activities, including the transfer of business units to subsidiaries.

**5. Shareholding Patterns:**

| Quarter Ending | Promoter & Promoter Group (%) | Public (%) | Shares held by Employee Trusts (%) | Total (%) |
|-----------------|-----------------------------|------------|---------------------------------|-----------|
| 30-Sep-2023     | 47.06                        | 52.94      | 0.00                           | 100.00    |
| 31-Dec-2023     | 47.04                        | 52.96      | 0.00                           | 100.00    |
| 31-Mar-2024     | 47.01                        | 52.99      | 0.00                           | 100.00    |
| 30-Jun-2024     | 46.98                        | 53.02      | 0.00                           | 100.00    |
| 30-Sep-2024     | 46.96                        | 53.04      | 0.00                           | 100.00    |

Promoter shareholding has shown a slight downward trend over the past year, while public shareholding has increased correspondingly. This trend warrants further investigation.

**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the significant difference between the week's high and low prices.  The CM Annual Volatility of 31.91% further confirms this.  The low market depth adds to the risk, making the stock susceptible to sharp price movements.  The risk-reward profile appears unfavorable given the current financial performance and high volatility.

**7. Advantages of Buying the Stock:**

* **Established Company:** Lupin is a well-established player in the pharmaceutical industry.
* **Dividend History:**  A history of dividend payments.

**8. Disadvantages and Risks:**

* **Consistent Losses:**  The company has reported losses for the past five quarters.
* **High Volatility:** The stock price is highly volatile.
* **Low Market Depth:**  Limited liquidity increases the risk of significant price swings.
* **Corporate Restructuring:**  Ongoing restructuring activities introduce uncertainty.

**9. Investment Horizon Recommendations:**

* **Short-Term (less than 3 months): Don't Buy.** The high volatility and recent negative price movement make a short-term investment risky.  The low market depth increases the risk of losses.

* **Medium-Term (3 to 12 months): Hold (if you have stock), Don't Buy (if you don't).**  The medium-term outlook depends heavily on the company's ability to reverse its current financial losses and stabilize its operations.  The ongoing restructuring needs to be carefully monitored.

* **Long-Term (1 year and beyond): Don't Buy.**  The consistent losses and high volatility make a long-term investment in Lupin currently unattractive.  Fundamental improvements are needed before considering a long-term investment.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 4/10**

* **Financial Health (2/10):**  Consistent losses significantly impact the score.
* **Market Performance (3/10):**  Moderate price, but high volatility and negative recent trend.
* **Volatility and Risk (1/10):** High volatility and low market depth contribute to high risk.
* **Corporate Actions and Governance (5/10):**  Dividend history is positive, but restructuring introduces uncertainty.
* **Shareholding Patterns (3/10):**  Slight decline in promoter holding warrants further investigation.

**Analysis Score (out of 10): 8/10**

* **Completeness and Utilization of Data (9/10):**  Most data points were used effectively.
* **Accuracy and Clarity of Analysis (7/10):**  Analysis is clear, but some data inconsistencies require further investigation.
* **Professional Formatting (9/10):**  Report is well-structured and easy to read.


**11. Professional Recommendation Summary:**

Given the consistent losses, high volatility, and low market depth, Lupin Limited is not recommended for investment in the short-term or long-term.  If an investor already holds the stock, a "hold" strategy for the medium term is suggested, pending a significant improvement in the company's financial performance and a clearer picture of the impact of its restructuring efforts.  Continuous monitoring of financial statements and corporate announcements is crucial for any decision regarding this stock.  Further investigation into the discrepancies in the provided financial data is strongly recommended.
